Highlights

  • Biome Australia reported record FY26 sales Revenue of approximately $23.9 million.
  • The company’s Activated Probiotics Brand expanded its presence in Australian community pharmacies.
  • Biome reported eight consecutive quarters of positive EBITDA.
  • A Manufacturing agreement with Specialty Probiotics Australia is expected to support future production activities.

Biome Australia (ASX:BIO) is a health products company focused on developing and distributing evidence-based probiotic and complementary medicine products. The company’s Activated Probiotics brand has continued expanding through pharmacy channels, supporting revenue growth and improving profitability.

At the time of writing on 14 August 2026, Biome Australia (ASX:BIO) was trading at AUD 0.28, down 3.39% on the day.

The company’s focus remains on scaling its probiotic product portfolio, strengthening manufacturing capabilities and expanding its market presence in Australia and overseas.

What Just Happened?

In July 2026, Biome Australia reported record FY26 sales revenue of approximately $23.9 million, representing growth of around 30% compared with the prior year.

The company stated that sales revenue had compounded at approximately 60% annually since 2021 as the Activated Probiotics brand expanded from a smaller base.

Australian same-store sales increased approximately 39% across channels, while June was estimated to be the first month where sell-through exceeded 100,000 units. International sales increased 26% to $1.8 million.

Earlier H1 FY26 results for the six months ended December 2025 showed revenue of approximately $12.4 million, up around 40%, with record half-year EBITDA of $1.47 million excluding share-based payments. Net profit increased 172% to $1.18 million, with gross Margin of approximately 61%.

In June 2026, Biome also entered into a binding manufacturing agreement with Specialty Probiotics Australia, with the first commercial batch targeted for September.

Why It Matters

Biome’s continued revenue growth alongside positive EBITDA performance highlights the company’s transition from an early-stage health products Business toward a more established operating model.

The growth in same-store sales is important because it indicates increased product Demand within existing pharmacy channels rather than relying only on additional distribution points.

The company’s manufacturing agreement with Specialty Probiotics Australia may provide greater control over production, quality management and product development as volumes increase.

However, maintaining growth rates from a larger revenue base remains an important challenge. Future performance will depend on continued customer demand, pharmacy channel performance and effective Supply chain management.

The Bigger Picture

Biome Australia develops and distributes complementary medicines, with the Activated Probiotics range forming the core of its business. The company primarily sells through Australian community pharmacies, where product awareness and pharmacist recommendations influence customer purchasing decisions.

The company differentiates its products through evidence-based probiotic formulations using specific strains targeted at particular health requirements.

Biome has expanded its position within the community pharmacy probiotic category while also developing international sales channels. Offshore revenue remains a smaller component of the overall business but represents an additional growth pathway.

The company’s financial profile combines a gross margin of approximately 61% with an operating structure designed to support continued expansion. The move toward dedicated manufacturing arrangements forms part of its broader strategy to manage more aspects of the supply chain.

What Could Drive the Shares Next?

The upcoming audited FY26 results will provide further detail on full-year profitability, cash position and operating performance.

Investors will monitor whether the margin profile achieved during H1 FY26 continued through the second half and whether sales growth translated into sustained profitability.

The first commercial batch under the Specialty Probiotics Australia manufacturing agreement, targeted for September, will be another operational milestone.

Further expansion of pharmacy distribution, product range development and international sales growth may also influence future performance.

Risks Investors Should Watch

Biome faces risks related to consumer demand, competition, manufacturing execution and regulatory requirements. The company remains reliant on the pharmacy channel and the performance of its probiotic product portfolio. Increased competition from larger healthcare and supplement businesses may affect Market Share and Marketing requirements. The transition to a new manufacturing arrangement could involve supply or execution challenges. Maintaining rapid growth from a smaller revenue base may become more difficult over time. As a smaller ASX-listed company, Biome also faces liquidity risks and may require additional Capital to support expansion.

Bottom Line

Biome Australia (ASX:BIO) has continued expanding its Activated Probiotics business, reporting record FY26 sales revenue of approximately $23.9 million and maintaining a track record of positive EBITDA performance.

The company is focused on strengthening its pharmacy presence, expanding its product offering and improving supply chain control through its manufacturing agreement.

The next stage will depend on sustaining revenue growth, protecting margins and successfully managing production expansion. The upcoming full-year results and manufacturing milestones will provide further insight into the durability of the company’s growth strategy.